Holder evidence
8
SEC ownership of Regulus Therapeutics Inc.
Top holders, 13D/G large-stake signals, insider positions, and transaction flow tied to CIK 0001505512.
Lead holder
Vivo Opportunity Fund Holdings, L.P.
13D/G signal
Vivo Opportunity Fund Holdings, L.P.
Latest evidence
30 Jun 2025
- CIK
- 0001505512
- Location
- San Diego, CA
- SEC evidence mix
- 13D/G and 3/4/5
- Lead holder
- Vivo Opportunity Fund Holdings, L.P.
- Latest large-stake holder
- Vivo Opportunity Fund Holdings, L.P.
- Latest evidence date
- 30 Jun 2025
Issuer identity
Ownership snapshot
Ownership snapshot
Top shareholders of Regulus Therapeutics Inc. (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Lead holder
Vivo Opportunity Fund Hol...
13D/G signal
Vivo Opportunity Fund Hol...
Evidence rows
8
Latest as of
30 Jun 2025
13D/G
3/4/5
Lead comparable stake: 3.9%
13D/G row: Vivo Opportunity Fund Holdings, L.P.
Rank 1 holder
Vivo Opportunity Fund Holdings, L.P.
13D/G
- Ownership
- 3.9%
- Position
- $9.09M
Rank 2 holder
Point72 Asset Management, L.P.
13D/G
- Ownership
- 0.3%
- Position
- $1.98M
Rank 3 holder
Denis Drygin
3/4/5
- Ownership
- —
- Position
- $119.1K
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| Vivo Opportunity Fund Holdings, L.P. |
13D/G
|
3.9%
|
$9,086,956
2,696,426 shares
|
$0 | 31 Mar 2025 |
| Point72 Asset Management, L.P. |
13D/G
|
0.3%
|
$1,977,487
241,157 shares
|
-$30,197,722 | 30 Jun 2025 |
| Denis Drygin |
3/4/5
Chief Scientific Officer
|
—
class O/S missing
|
$119,060
100,000 shares
|
— | 01 Mar 2022 |
| Joseph P. Hagan |
3/4/5
Chief Executive Officer, Director
|
—
class O/S missing
|
—
1,350,000 shares
|
— | 25 Jun 2025 |
| Preston Klassen |
3/4/5
President & Head of R & D, Director
|
—
class O/S missing
|
—
675,000 shares
|
+$95,852 | 25 Jun 2025 |
| Crispina Calsada |
3/4/5
Chief Financial Officer
|
—
class O/S missing
|
—
562,500 shares
|
— | 25 Jun 2025 |
| Christopher Ray Aker |
3/4/5
Sr. VP & General Counsel
|
—
class O/S missing
|
—
487,500 shares
|
— | 25 Jun 2025 |
| Simos Simeonidis |
3/4/5
Director
|
—
class O/S missing
|
—
90,000 shares
|
— | 09 Jun 2022 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
Forms 3/4/5 flow
Insider trading overview
Net insider flow leans to buying over the last 12 months. Net value: +$95,852.
Buys
$95,852
Insiders: 1
Sells
$0
Insiders: 0
Net
+$95,852
Shares: +12,000
Window
Last 12 months
4 rolling buckets
Buy value
Sell value
Shares: 12,000
Shares: 0
| Window (months) | Buy shares | Sell shares | Buy value | Sell value | Net value |
|---|---|---|---|---|---|
| 0-3 | 0 | 0 | $0 | $0 | $0 |
| 3-6 | 0 | 0 | $0 | $0 | $0 |
| 6-9 | 0 | 0 | $0 | $0 | $0 |
| 9-12 | 12,000 | 0 | $95,852 | $0 | +$95,852 |
Reporting owners
Insider holders from Forms 3/4/5
Showing 1-14 of 14 reporting-owner rows connected to Regulus Therapeutics Inc.. Open a relationship link for the CIK-to-CIK filing trail.
Rows
14
Lead holder
Denis Drygin
Net 12M change
+$95,852
Latest report
25 Jun 2025
| Name | Relationship | Holdings Value | Past Year Net Change | Change % | Valuation | Report Date |
|---|---|---|---|---|---|---|
| Denis Drygin | Chief Scientific Officer | $119,060 | Mixed | 01 Mar 2022 | ||
| Joseph P. Hagan | Chief Executive Officer, Director | $0 | Mixed | 25 Jun 2025 | ||
| Christopher Ray Aker | Sr. VP & General Counsel | $0 | Mixed | 25 Jun 2025 | ||
| Stelios Papadopoulos | Director | $0 | Mixed | 25 Jun 2025 | ||
| William H. Rastetter | Director | $0 | Mixed | 25 Jun 2025 | ||
| Alice Shih-Hou Huang | Director | $0 | Mixed | 25 Jun 2025 | ||
| Pascale Witz | Director | $0 | Mixed | 25 Jun 2025 | ||
| Preston Klassen | President & Head of R & D, Director | $0 | +$95,852 | Mixed | 25 Jun 2025 | |
| Kathryn J. Collier | Director | $0 | Mixed | 25 Jun 2025 | ||
| Hugh Rosen | Director | $0 | Mixed | 25 Jun 2025 | ||
| Crispina Calsada | Chief Financial Officer | $0 | Mixed | 25 Jun 2025 | ||
| Jason Raleigh Nunn | Director | $0 | Mixed | 25 Jun 2025 | ||
| David Baltimore | Director | $0 | Mixed | 25 Jun 2025 | ||
| Simos Simeonidis | Director | Mixed | 09 Jun 2022 |
Recent insider transactions for Regulus Therapeutics Inc.
Showing up to 300 most recent insider transactions from the last 12 months.
| Insider | Symbol | Class | Transaction | % | Reported value | Reported price | Shares | Shares owned | Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|---|
| William H. Rastetter | RGLS | Common Stock | Disposed to Issuer | -100% | -57,292 | 0 | 25 Jun 2025 | By The Rastetter Family Trust | ||
| William H. Rastetter | RGLS | Common Stock | Disposition pursuant to a tender of shares in a change of control transaction | -43.6% | -44,264 | 57,292 | 25 Jun 2025 | By The Rastetter Family Trust | ||
| William H. Rastetter | RGLS | Stock Option | Disposed to Issuer | -100% | -154,975 | 0 | 25 Jun 2025 | By The Rastetter Family Trust | ||
| Pascale Witz | RGLS | Common Stock | Disposed to Issuer | -100% | -67,233 | 0 | 25 Jun 2025 | Direct | ||
| Pascale Witz | RGLS | Class A-2 Convertible Preferred Stock | Disposed to Issuer | -100% | -677 | 0 | 25 Jun 2025 | Direct | ||
| Pascale Witz | RGLS | Stock Option | Disposed to Issuer | -100% | -154,975 | 0 | 25 Jun 2025 | Direct | ||
| Stelios Papadopoulos | RGLS | Common Stock | Disposed to Issuer | -100% | -64,635 | 0 | 25 Jun 2025 | Direct | ||
| Stelios Papadopoulos | RGLS | Common Stock | Disposition pursuant to a tender of shares in a change of control transaction | -93.8% | -976,253 | 64,635 | 25 Jun 2025 | Direct | ||
| Stelios Papadopoulos | RGLS | Common Stock Purchase Warrant (Right to Buy) | Disposed to Issuer | -100% | -59,514 | 0 | 25 Jun 2025 | Direct | ||
| Stelios Papadopoulos | RGLS | Stock Option | Disposed to Issuer | -100% | -154,975 | 0 | 25 Jun 2025 | Direct | ||
| Hugh Rosen | RGLS | Common Stock | Disposed to Issuer | -100% | -57,292 | 0 | 25 Jun 2025 | Direct | ||
| Hugh Rosen | RGLS | Common Stock | Disposition pursuant to a tender of shares in a change of control transaction | -10.9% | -6,979 | 57,292 | 25 Jun 2025 | Direct | ||
| Hugh Rosen | RGLS | Stock Option | Disposed to Issuer | -100% | -154,975 | 0 | 25 Jun 2025 | Direct | ||
| Preston Klassen | RGLS | Common Stock | Disposed to Issuer | -100% | -115,555 | 0 | 25 Jun 2025 | Direct | ||
| Preston Klassen | RGLS | Stock Option | Disposed to Issuer | -100% | -1,898,000 | 0 | 25 Jun 2025 | Direct | ||
| Christopher Ray Aker | RGLS | Common Stock | Disposed to Issuer | -100% | -83,125 | 0 | 25 Jun 2025 | Direct | ||
| Christopher Ray Aker | RGLS | Common Stock | Disposition pursuant to a tender of shares in a change of control transaction | -42.2% | -60,796 | 83,125 | 25 Jun 2025 | Direct | ||
| Christopher Ray Aker | RGLS | Stock Option | Disposed to Issuer | -100% | -1,472,000 | 0 | 25 Jun 2025 | Direct | ||
| Joseph P. Hagan | RGLS | Common Stock | Disposed to Issuer | -100% | -571,558 | 0 | 25 Jun 2025 | Direct | ||
| Joseph P. Hagan | RGLS | Common Stock Purchase Warrant (Right to Buy) | Disposed to Issuer | -100% | -2,976 | 0 | 25 Jun 2025 | Direct | ||
| Joseph P. Hagan | RGLS | Stock Option | Disposed to Issuer | -100% | -4,389,000 | 0 | 25 Jun 2025 | Direct | ||
| David Baltimore | RGLS | Common Stock | Disposed to Issuer | -100% | -57,292 | 0 | 25 Jun 2025 | By Spouse | ||
| David Baltimore | RGLS | Common Stock | Disposition pursuant to a tender of shares in a change of control transaction | -8.33% | -5,208 | 57,292 | 25 Jun 2025 | By Spouse | ||
| David Baltimore | RGLS | Common Stock | Disposed to Issuer | -100% | -57,292 | 0 | 25 Jun 2025 | Direct | ||
| David Baltimore | RGLS | Common Stock | Disposition pursuant to a tender of shares in a change of control transaction | -32.3% | -27,377 | 57,292 | 25 Jun 2025 | Direct | ||
| David Baltimore | RGLS | Stock Option | Disposed to Issuer | -100% | -148,000 | 0 | 25 Jun 2025 | By Spouse | ||
| David Baltimore | RGLS | Stock Option | Disposed to Issuer | -100% | -154,975 | 0 | 25 Jun 2025 | Direct | ||
| Jason Raleigh Nunn | RGLS | Common Stock | Disposed to Issuer | -100% | -62,500 | 0 | 25 Jun 2025 | Direct | ||
| Jason Raleigh Nunn | RGLS | Stock Option | Disposed to Issuer | -100% | -154,975 | 0 | 25 Jun 2025 | Direct | ||
| Alice Shih-Hou Huang | RGLS | Common Stock | Disposed to Issuer | -100% | -57,292 | 0 | 25 Jun 2025 | By Spouse | ||
| Alice Shih-Hou Huang | RGLS | Common Stock | Disposition pursuant to a tender of shares in a change of control transaction | -32.3% | -27,377 | 57,292 | 25 Jun 2025 | By Spouse | ||
| Alice Shih-Hou Huang | RGLS | Common Stock | Disposed to Issuer | -100% | -57,292 | 0 | 25 Jun 2025 | Direct | ||
| Alice Shih-Hou Huang | RGLS | Common Stock | Disposition pursuant to a tender of shares in a change of control transaction | -8.33% | -5,208 | 57,292 | 25 Jun 2025 | Direct | ||
| Alice Shih-Hou Huang | RGLS | Stock Option | Disposed to Issuer | -100% | -154,975 | 0 | 25 Jun 2025 | By Spouse | ||
| Alice Shih-Hou Huang | RGLS | Stock Option | Disposed to Issuer | -100% | -148,000 | 0 | 25 Jun 2025 | Direct | ||
| Kathryn J. Collier | RGLS | Common Stock | Disposed to Issuer | -100% | -75,565 | 0 | 25 Jun 2025 | Direct | ||
| Kathryn J. Collier | RGLS | Stock Option | Disposed to Issuer | -100% | -148,650 | 0 | 25 Jun 2025 | Direct | ||
| Crispina Calsada | RGLS | Common Stock | Disposed to Issuer | -100% | -140,228 | 0 | 25 Jun 2025 | Direct | ||
| Crispina Calsada | RGLS | Stock Option | Disposed to Issuer | -100% | -1,628,500 | 0 | 25 Jun 2025 | Direct | ||
| Kathryn J. Collier | RGLS | Common Stock | Options Exercise | 8.17% | 4,929 | 65,240 | 17 Jun 2025 | Direct | ||
| Kathryn J. Collier | RGLS | Stock Option (Right to Buy) | Options Exercise | -100% | -4,929 | 0 | 17 Jun 2025 | Direct | ||
| Kathryn J. Collier | RGLS | Common Stock | Options Exercise | 2.1% | 1,396 | 67,844 | 16 Jun 2025 | Direct | ||
| Kathryn J. Collier | RGLS | Stock Option (Right to Buy) | Options Exercise | -34.9% | -1,396 | 2,604 | 16 Jun 2025 | Direct | ||
| Preston Klassen | RGLS | Common Stock | Purchase | 33.3% | $95,852 | $7.99 | 12,000 | 48,055 | 03 Jun 2025 | Direct |
* indicates a reported price that failed the local validity check.